| Autor: |
Rachid Z; Cancer Drug Research Laboratory, Division of Medical Oncology, Department of Medicine, McGill University/Royal Victoria Hospital, 687 Pine Avenue West Rm. M-719, Montreal, Que., Canada H3A 1A1., Katsoulas A, Williams C, Larroque AL, McNamee J, Jean-Claude BJ |
| Jazyk: |
angličtina |
| Zdroj: |
Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2007 Aug 01; Vol. 17 (15), pp. 4248-53. Date of Electronic Publication: 2007 May 24. |
| DOI: |
10.1016/j.bmcl.2007.05.067 |
| Abstrakt: |
Steps toward the identification of combi-molecules with strong abl tyrosine kinase (TK) inhibitory property and significant DNA damaging potential are described. The optimized combi-molecule 13a was shown to induce approximately twofold stronger abl TK inhibitory activity than Gleevec and high levels of DNA damage in chronic myelogenous leukemic cells. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect